Last updated: February 15, 2026
Drug Overview
NDC 00597-0116 corresponds to Xyrem (sodium oxybate), prescribed primarily for narcolepsy with cataplexy and excessive daytime sleepiness. It is a Schedule III controlled substance, recognized for its sedative and anxiolytic effects.
Market Size and Demand Drivers
The global narcolepsy treatment market has grown steadily, driven by increased diagnosis rates, advances in diagnostic tools, and expanding awareness. Industry estimates forecast a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2022-2027, reaching USD 1.6 billion by 2027.[1]
Xyrem remains the primary FDA-approved therapy for cataplexy and narcolepsy, with a substantial market share due to its well-established efficacy profile. As of 2022, the U.S. market for sodium oxybate formulations (including Xyrem) generated approximately USD 800 million.[2]
Competitive Landscape
No direct generic equivalents are present to date. The drug’s patent exclusivity expired in 2028, with some formulations still under patent in certain jurisdictions until 2030. Regulatory pathways for generic sodium oxybate are complicated by its Schedule III status and the need for specialized manufacturing.
Key competitors include off-label sedative treatments and potential imports from countries with less regulation, but these do not match Xyrem’s approval status.
Pricing Structure and Trends
- Current Wholesale Price: The average wholesale price (AWP) for a 30-day supply of Xyrem (each containing 5 grams/day dosage) is approximately USD 2,300 to USD 2,600 per month.[3]
- Manufacturing and Distribution Costs: Given the complex synthesis and strict handling requirements, manufacturing costs are estimated at 15-20% of the retail price.
- Reimbursement Policies: Insurance coverage is generally comprehensive, with Medicaid and Medicare Part D coverages routinely available. Reimbursement rates influence retail price trends.
Historical Price Trends
Over the past five years, the price of Xyrem has increased approximately 4-6% annually, influenced by manufacturing costs, regulatory compliance, and market demand. This trend is expected to continue as demand remains resilient and potential supply constraints persist.
Future Price Projections
- Short-term (1-2 years): Prices are estimated to stabilize around USD 2,400 to USD 2,700 per month, contingent upon inflation, reimbursement policy adjustments, and market supply stability.
- Medium-term (3-5 years): Introduction of generic sodium oxybate formulations could lower prices by 20-40%. However, current legal and regulatory challenges may delay generic entry, extending brand dominance.
- Long-term (5+ years): Assuming patent expiration and regulatory approvals for generics, prices could decrease by approximately 50%, potentially lowering treatment costs to USD 1,200 per month.
Regulatory and Policy Impacts
FDA approval of generics depends on demonstrating bioequivalence while satisfying Schedule III controls. Recent policies favoring biosimilar entry in other therapeutic areas suggest a potential pathway for simplified approval, but the Schedule III designation complicates this process for sodium oxybate.
Market Risks
- Regulatory delays in approving generics.
- Changes in insurance reimbursement policies.
- Emergence of new therapies with improved efficacy or safety profiles.
- Shifts in clinical practice favoring alternative treatments.
Key Takeaways
- The current market for Xyrem is valued around USD 800 million in the U.S. with pricing stabilized around USD 2,400/month.
- Patent expirations forecast potential price reductions within 3-5 years, depending on generic entry.
- Price sensitivity will hinge on regulatory hurdles, reimbursement policies, and competition from alternative treatments.
- Continued demand growth is supported by increased diagnosis rates of narcolepsy and sleep disorders.
FAQs
1. When will generic sodium oxybate become available?
Potentially in 2028-2030, contingent on patent expiry and regulatory approval processes, which are complicated by Schedule III controls.
2. How might price trends evolve post-generic entry?
Prices could decrease by up to 40-50%, aligning closer to manufacturing costs, provided market competition intensifies.
3. What factors could delay generic entry?
Stringent regulatory requirements, manufacturing complexities, and legal challenges related to the controlled substance status.
4. Are there biosimilar or alternative therapies in development?
Biosimilars are unlikely due to the drug’s small molecule nature and regulatory status. Alternative therapies are under investigation but have yet to reach FDA submission.
5. How does insurance coverage influence pricing?
Reimbursement policies support steady demand; changes could affect retail price and patient access.
Citations
- Grand View Research, "Narcolepsy Treatment Market," 2022.
- IQVIA, "US Market Data," 2022.
- Red Book, "Xyrem Wholesale Price," 2022.
[1] Grand View Research, “Narcolepsy Treatment Market Analysis 2022-2027”
[2] IQVIA, “U.S. Pharmaceutical Market Trends,” 2022
[3] Red Book, “Wholesale Price Data,” 2022
